WallStSmart
ABCL

Abcellera Biologics Inc

NASDAQ: ABCL · HEALTHCARE · BIOTECHNOLOGY

$3.82
-8.17% today

Updated 2026-04-29

Market cap
$1.16B
P/E ratio
P/S ratio
15.41x
EPS (TTM)
$-0.49
Dividend yield
52W range
$2 – $7
Volume
4.0M

Abcellera Biologics Inc (ABCL) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20182019202020212022202320242025
Revenue$8.83M$11.61M$233.16M$11.61M$485.42M$38.02M$28.83M$75.13M
Revenue growth (YoY)+31.5%+1907.9%-95.0%+4080.5%-92.2%-24.2%+160.6%
Cost of revenue$5.80M$10.11M$27.14M$45.52M$66.44M$30.89M$97.00M
Gross profit$8.83M$11.61M$206.01M$11.61M$418.99M$38.02M$28.83M$75.13M
Gross margin100.0%100.0%88.4%100.0%86.3%100.0%100.0%100.0%
R&D$5.80M$10.11M$29.39M$62.06M$107.88M$175.66M$167.26M$186.83M
SG&A$2.15M$2.75M$11.91M$2.75M$55.48M$61.00M$72.71M$83.23M
Operating income$-753000.00$-4.12M$156.03M$-4.12M$216.51M$-237.21M$-314.77M$-217.10M
Operating margin-8.5%-35.5%66.9%-35.5%44.6%-623.8%-1091.7%-289.0%
EBITDA$1.44M$-155000.00$169.62M$-154612.00$260.17M$-192.16M$-204.15M$-155.42M
EBITDA margin16.3%-1.3%72.7%-1.3%53.6%-505.3%-708.0%-206.9%
EBIT$521000.00$-2.00M$164.34M$-2.00M$227.06M$-223.05M$-301.15M$-177.59M
Interest expense$212000.00$209000.00$6.51M$209196.00$4.04M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$309000.00$-2.21M$118.92M$-2.21M$158.52M$-146.40M$-162.86M$-146.41M
Net income growth (YoY)-815.5%+5478.5%-101.9%+7270.5%-192.4%-11.2%+10.1%
Profit margin3.5%-19.0%51.0%-19.0%32.7%-385.0%-564.8%-194.9%